 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*
Department of Pathology, Columbia College of Physicians and Surgeons, New
York, New York
Department of Medicine, Division of Nephrology, Columbia College of
Physicians and Surgeons, New York, New York
Division of Nephrology, Department of Internal Medicine, Morristown
Memorial Hospital/Atlantic Health System, Morristown, New Jersey
Nephrology Division, Baylor University Medical Center, Dallas,
Texas
||
Division of Nephrology, Department of Internal Medicine, Hilton Head
Medical Center, Hilton Head Island, South Carolina
¶
Department of Medicine, New York Medical College, New York, New
York
#
Department of Medicine, Division of Nephrology, Medical Center of
Delaware, Newark, Delaware
**
Lehigh Valley Nephrology Associates, Bethlehem, Pennsylvania.
Correspondence to Dr. Vivette D. D'Agati, Department of Pathology, Columbia College of Physicians and Surgeons, 630 W. 168th Street, VC 14-224, New York, NY 10032. Phone: 212-305-7460; Fax: 212-342-5380; E-mail: vddl{at}columbia.edu
Abstract. Collapsing focal segmental glomerulosclerosis (FSGS) is a distinct clinicopathologic entity seen most commonly in young African American patients who present with renal insufficiency and nephrotic syndrome. The only epidemiologic factor previously linked to collapsing FSGS is HIV infection. Here clinicopathologic findings are reported for a distinctive population of seven patients, who were older, Caucasian, and HIV negative and developed collapsing FSGS during active treatment of malignancy (multiple myeloma in six patients and metastatic breast carcinoma in one). Although oncologic treatment regimens included vincristine for four patients, doxorubicin for five patients, cisplatin for two patients, and total-body irradiation for one patient, the only agent common to all patients was pamidronate (Aredia). All patients had normal renal function before the administration of pamidronate. Patients began therapy with pamidronate at or below the recommended dose of 90 mg, intravenously, monthly, which was increased to 180 mg monthly in two patients and 360 mg monthly in three patients. Patients received pamidronate for 15 to 48 mo before presentation with renal insufficiency (mean serum creatinine, 3.6 mg/dl) and full nephrotic syndrome (mean 24-h urinary protein excretion, 12.4 g/d). Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases. At the recommended dose of 90 mg, intravenously, monthly, renal toxicity is infrequent; however, higher doses have produced nephrotoxicity in animal models. The temporal association between pamidronate therapy and the development of renal insufficiency, the use of escalating doses that exceed recommended levels, and the distinctive pattern of glomerular and tubular injury strongly suggest a mechanism of drug-associated podocyte and tubular toxicity. These data provide the first association of collapsing FSGS with toxicity to a therapeutic agent.
This article has been cited by other articles:
 |
|
 |
|
  R. von Moos, C. B. Caspar, B. Thurlimann, R. Angst, R. Inauen, R. Greil, B. Bergstrom, K. Schmieding, and M. Pecherstorfer Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study Ann. Onc., July 1, 2008; 19(7): 1266 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Olson and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bodmer, P. Amico, M. J. Mihatsch, M. Haschke, O. Kummer, S. Krahenbuhl, and M. Mayr Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2366 - 2370. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Fujii, T. Hamano, S. Mikami, Y. Nagasawa, Y. Isaka, T. Moriyama, M. Horio, E. Imai, M. Hori, and T. Ito Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1601 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. Goes and R. B. Colvin Case 12-2007 -- A 56-Year-Old Woman with Renal Failure after Heart-Lung Transplantation N. Engl. J. Med., April 19, 2007; 356(16): 1657 - 1665. [Full Text] [PDF]
|
|
|
|
|
|
M. L de Lemos, S. C Taylor, J. B Barnett, F. Hu, A. Levin, V. Moravan, and S. E O'Reilly Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 193 - 199. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Albaqumi, T. J. Soos, L. Barisoni, and P. J. Nelson Collapsing Glomerulopathy J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2854 - 2863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Korbet and M. M. Schwartz Multiple Myeloma J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2533 - 2545. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cameron, M. Fallon, and I. Diel Ibandronate: Its Role in Metastatic Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zheng, P. Pavlidis, S. Chua, V. D. D'Agati, and A. G. Gharavi An Ancestral Haplotype Defines Susceptibility to Doxorubicin Nephropathy in the Laboratory Mouse J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1796 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanvetyanon and P. J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann. Onc., June 1, 2006; 17(6): 897 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Grover, S Shankar, R Aneja, V Marwaha, R Gupta, and A Kumar Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis, May 1, 2006; 65(5): 688 - 689. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mehrotra and S. Ruggiero Bisphosphonate Complications Including Osteonecrosis of the Jaw Hematology, January 1, 2006; 2006(1): 356 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Guarneri, S. Donati, M. Nicolini, S. Giovannelli, R. D'Amico, and P. F. Conte Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years Oncologist, November 1, 2005; 10(10): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L P. Marques, G G. Pacheco, L S Rioja, S N Nunes, S T Velone, and O R Santos Can systemic lupus erythematosus be the cause of collapsing glomerulopathy? Lupus, October 1, 2005; 14(10): 853 - 855. [Abstract] [PDF]
|
|
|
|
|
|
L. Barisoni, M. P. Madaio, M. Eraso, D. L. Gasser, and P. J. Nelson The kd/kd Mouse Is a Model of Collapsing Glomerulopathy J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2847 - 2851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Body, T. Pfister, and F. Bauss Preclinical Perspectives on Bisphosphonate Renal Safety Oncologist, October 1, 2005; 10(suppl_1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Munier, V. Gras, M. Andrejak, N. Bernard, M.-J. Jean-Pastor, S. Gautier, M. Biour, and Z. Massy Zoledronic Acid and Renal Toxicity: Data from French Adverse Effect Reporting Database Ann. Pharmacother., July 1, 2005; 39(7): 1194 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Balla The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View Oncologist, May 1, 2005; 10(5): 306 - 308. [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer J. Clin. Oncol., February 1, 2005; 23(4): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Humphreys, R. J. Soiffer, and C. C. Magee Renal Failure Associated with Cancer and Its Treatment: An Update J. Am. Soc. Nephrol., January 1, 2005; 16(1): 151 - 161. [Full Text] [PDF]
|
|
|
|
|
|
S. Lee, D. Glicklich, and M. Coco Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2870 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Conte and V. Guarneri Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens Oncologist, September 1, 2004; 9(suppl_4): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Magee and M. Pascual Update in Renal Transplantation Arch Intern Med, July 12, 2004; 164(13): 1373 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berenson and R. Hirschberg Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, June 1, 2004; 9(3): 319 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kunin, J. Kopolovic, A. Avigdor, and E. J. Holtzman Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient Nephrol. Dial. Transplant., March 1, 2004; 19(3): 723 - 726. [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Silva Chemical-Induced Nephropathy: A Review of the Renal Tubulointerstitial Lesions in Humans Toxicol Pathol, February 1, 2004; 32(2_suppl): 71 - 84. [Abstract] [PDF]
|
|
|
|
|
|
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Ladewski, S. M. Belknap, J. R. Nebeker, O. Sartor, E. A. Lyons, T. C. Kuzel, M. S. Tallman, D. W. Raisch, A. R. Auerbach, G. T. Schumock, et al. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project J. Clin. Oncol., October 15, 2003; 21(20): 3859 - 3866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buysschaert, J.-P. Cosyns, L. Barreto, and M. Jadoul Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism Nephrol. Dial. Transplant., April 1, 2003; 18(4): 826 - 829. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ross and P. E. Klotman Recent Progress in HIV-Associated Nephropathy J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2997 - 3004. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Stratton and P. Warwicker Relapse of nephrotic syndrome triggered by biphosphonates Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1856 - 1857. [Full Text]
|
|
|
|
|
|
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
